Company / Accounts Receivable
ANI Pharmaceuticals, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$281.1M
FY2025
5-year range
$128.5M / $281.1M
FY2021-FY2025
Trend
+26.8%
vs FY2024
Sector context
#29 of 113
Health Care
What the data says
At $281M, ANI Pharmaceuticals, Inc.'s accounts receivable ranks #29 of 113 in the Health Care sector. Improved from $162M to $281M over the past 2 years.
Based on SEC 10-K filings.
$281M in FY2025 with a 5-year CAGR of +24.0%. Top quartile in the Health Care sector.
Improved from $162M to $281M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +19.3%
- 5-Year CAGR
- +24.0%
- 10-Year CAGR
- -
Sector benchmark
#29 of 113 in Health CareTop 26% of 113This company $281.1M Sector average $1.1B
▼
-75.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +24.0%, indicating consistent growth.
- In FY2025, accounts receivable increased 26.8% year-over-year.
- Ranks #29 out of 113 companies in the Health Care sector.
- Lowest accounts receivable in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $281.1M | +26.8% |
| FY2024 | $221.7M | +36.8% |
| FY2023 | $162.1M | -2.0% |
| FY2022 | $165.4M | +28.7% |
| FY2021 | $128.5M | +34.2% |
| FY2020 | $95.8M | +32.8% |
| FY2019 | $72.1M | +11.2% |
| FY2018 | $64.8M | +10.3% |
| FY2017 | $58.8M | +28.1% |
| FY2016 | $45.9M | +109.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026